BullFrog AI is an investor-backed company determined to become the undisputed leader in precision medicine. Our mission is to find the link between therapies and patients, and improve their lives. Using our proprietary technology platform, we aim to predict which patients will benefit from which medications, effectively improving clinical outcomes and eliminating the problem of trial-and-error prescriptions.

We have an exceptional team of life science industry leaders, AI technologists, scientists, physicians and advisors determined to help BullFrog AI revolutionize drug development. Through our partnership with one of the most prestigious research institutions in the world, we take pride in technology innovation by staying on the cutting edge of AI.

BullFrog AI Leadership

Vin Singh

Founder and CEO

Mr. Singh is a dynamic visionary and experienced professional executive from the life sciences industry. He has extensive start-up experience having founded and built several companies in the life science space including BullFrog, Next Healthcare Inc., and MaxCyte Inc. Most recently, he led ThermoFisher Scientific’s global cell therapy services business. Vin has a BS in Electrical Engineering from Rutgers University, and MS in Biomedical Engineering from Rensselaer Polytechnic Institute, and an MBA from Johns Hopkins University. He is known for his strategic thinking, vision, and integrity.

BullFrog AI Advisors

Kristin Bigos

Dr. Kristin Bigos is an Assistant Professor of Medicine, Psychiatry, and Pharmacology at the Johns Hopkins University School of Medicine. Her research focuses on neuropsychiatric drug development and a precision medicine approach to the treatment of mental illness.

The Bigos Lab uses functional MRI as a biomarker to test the neural effects of drugs designed to treat symptoms of mental illness. Her lab currently has a pharmacoMRI study to develop a treatment for cognitive dysfunction in schizophrenia. Other studies aim to identify patient-specific variables including sex, race, and genetics that impact drug clearance and clinical response to better select and dose antipsychotics and antidepressants.

Dr. Bigos received her B.S. in Premedicine from the Pennsylvania State University. She earned her Ph.D. in Clinical Pharmaceutical Sciences from the University of Pittsburgh. She completed a post-doctoral fellowship in the Clinical Brain Disorders Branch of the Intramural Research Program of the National Institute of Mental Health under Dr. Daniel Weinberger. Before joining Johns Hopkins, she worked as an Investigator at the Lieber Institute for Brain Development.

Everett Lee

Mr. Lee brings over two decades of technology leadership experience as head of IT for the R&D divisions of leading global pharmaceutical/biotech and drug development companies such as AstraZeneca/MedImmune, Roche/Genentech, Eli Lilly & Co, Pfizer, and Covance. His focus has been leveraging technology innovations to spur business growth and profitability in scientific and government-regulated environments. Mr. Lee earned his B.A. in Chemistry from the University of Chicago, and his M.S. in Communication Systems Strategy and Management from Northwestern University.

Mr. Lee currently lives in Maryland with his wife, 3 kids and giant furry poodle. As a former triathlete and competitive swimmer, he enjoys living a healthy lifestyle and going on long hikes with his wife and family. He also has a passion for digital photography and home automation technology.